Form 4: Organon R&D Head Boosts Stake via RSU Vesting

Organon & Co.'s Head of R&D and CMO, Juan Camilo Arjona Ferreira, increased his direct ownership of common stock following the vesting of restricted stock units and a tax-related sale.

Summary

• Juan Camilo Arjona Ferreira, Organon & Co.'s Head of R&D and Chief Medical Officer, reported changes in his beneficial ownership of company securities.
• On August 11, 2025, 11,519 restricted stock units (RSUs) vested and were converted into common stock.
• Concurrently, 4,122 shares of common stock were disposed of at $9.22 per share, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, Mr. Ferreira's direct beneficial ownership of Organon common stock increased to 24,777.355 shares.
• He also retains beneficial ownership of 11,519 unvested restricted stock units, with the final vesting scheduled for August 11, 2026.

Sentiment

Score: 7

Explanation: The filing indicates a routine vesting of executive equity compensation, leading to a net increase in the executive's direct shareholding, which is generally viewed positively as it aligns management incentives with shareholder interests.

Positives

• A key executive, the Head of R&D and CMO, increased their direct beneficial ownership of Organon common stock by 7,397 shares.
• The vesting of restricted stock units indicates the fulfillment of long-term incentive compensation, aligning management interests with shareholder value.

Negatives

• A portion of the newly acquired shares (4,122 shares) was immediately sold at $9.22 per share, likely to cover tax liabilities, which reduces the net increase in the executive's direct stake.

Future Outlook

The remaining 11,519 restricted stock units held by the executive are scheduled for their final vesting on August 11, 2026.

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased alignment with management due to a net increase in executive ownership.
• Employees: Confirms the ongoing execution of standard executive compensation practices.

Next Steps

• Final vesting of 11,519 restricted stock units on August 11, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities. While it results in a net increase in the executive's direct ownership, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It primarily reflects standard compensation practices and insider ownership alignment.

Keywords

Organon, OGN, SEC Form 4, insider trading, stock ownership, executive compensation, restricted stock units, RSU, pharmaceutical, healthcare